Decreased risk of dementia in migraine patients with traditional Chinese medicine use: a population-based cohort study

Chun-Ting Liu1,*, Bei-Yu Wu1,*, Yu-Chiang Hung1,2,*, Lin-Yi Wang3, Yan-Yuh Lee3, Tsu-Kung Lin4, Pao-Yen Lin5, Wu-Fu Chen6, Jen-Huai Chiang7,8, Sheng-Feng Hsu9,10 and Wen-Long Hu1,11,12,*

1Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Kaohsiung, Taiwan
2School of Chinese Medicine for Post Baccalaureate, I-Shou University, Kaohsiung, Taiwan
3Department of Physical Medicine and Rehabilitation, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
4Department of Neurology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
5Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
6Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
7Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
8College of Medicine, China Medical University, Taichung, Taiwan
9Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan
10Department of Chinese Medicine, China Medical University Hospital, Taipei Branch, Taipei, Taiwan
11Kaohsiung Medical University College of Medicine, Kaohsiung, Taiwan
12Fooyin University College of Nursing, Kaohsiung, Taiwan

*These authors contributed equally to this work

Correspondence to: Wen-Long Hu, email: oolonghu@gmail.com

Keywords: dementia, migraine, pharmaco-epidemiology, national health insurance research database, Chinese herbal product

Received: February 27, 2017  Accepted: June 28, 2017  Published: July 08, 2017

Copyright: Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Patients with migraine are reportedly at increased risk of developing dementia. We aimed to investigate the association between traditional Chinese medicine (TCM) use and dementia risk in migraine patients. This longitudinal cohort study used the Taiwanese National Health Insurance Research Database to identify 32,386 diagnosed migraine patients aged 20 years and above who received treatment from 1997 to 2010. To balance comparability between TCM users and non-TCM users, we randomly selected equal numbers from each group, and compared subgroups compiled based on combinations of age, sex, index year, and year of migraine diagnosis. All enrollees received follow-up until the end of 2013 to measure dementia incidence. We identified 1,402 TCM users and non-TCM users after frequency matching. A total of 134 subjects were newly diagnosed with dementia during the follow-up period. TCM users were significantly less likely to develop dementia than non-TCM users. The most frequently prescribed formulae and single Chinese herbal products were Jia-Wei-Xiao-Yao-San and Yan-Hu-Suo, respectively. This population-based study revealed a decreased dementia risk in migraine patients with TCM use. These findings may provide a reference for dementia prevention strategies, and help integrate TCM into clinical intervention programs that provide a favorable prognosis for migraine patients.
INTRODUCTION

Migraine is a primary headache disorder characterized by recurrent episodes of moderate to severe pulsating headache, most often unilateral, that is aggravated by physical activity and associated with nausea, photophobia, or phonophobia [1]. Reports of migraine prevalence vary broadly. The reported prevalence of migraine is 15% in Europe, 13% in North America, 9% in Asia, and 5% in Africa [2]. Migraine can affect all age groups, but it most commonly occurs in females and those aged from 25 to 55 years old, the peak years of economic productivity [3]. Recently updated statistics from US government health surveillance studies show that migraine remains a highly prevalent medical condition, affecting approximately 15% of Americans annually [4].

Dementia is characterized by slow progressive deterioration in memory and cognitive function, and an inability to perform personal daily activities [5]. It is a neurodegenerative disorder that typically affects older people. With the global aging population, the number of patients with dementia will rise and place an increasing burden on families and the healthcare system [5]. A recent epidemiologic study has demonstrated that migraine is associated with an increased risk of developing dementia [6]. Thus, how to prevent the occurrence of dementia in patients with migraine is an essential public health issue.

Traditional Chinese medicine (TCM) is a form of complementary and alternative medicine (CAM) that has been widely applied for centuries in Asian countries. Since 1995, Chinese herbal products (CHPs) have been listed under the National Health Insurance (NHI) program, which is a government-run, single-payer program that covers more than 99% of Taiwanese citizens and over 93% of Taiwanese healthcare institutes [7]. In Taiwan, like Western medicine, TCM is widely used for the treatment of migraine. Increasing evidence suggests that reducing modifiable risk factors such as smoking, midlife hypertension, midlife obesity, and diabetes may reduce the prevalence of dementia [8]. In addition, some potentially protective medications for dementia have been reported such as antihypertensive drugs, statins, hormone replacement therapy, and non-steroidal anti-inflammatory drugs [9]. However, to the best of our knowledge, no studies have investigated the use of TCM for reducing the risk of dementia in migraine patients.

This population-based cohort study aimed to investigate the risk of dementia development in migraine patients with or without TCM use. We also identified the most commonly used CHPs in migraine sufferers.

RESULTS

Using data from January 1997 to December 2010, we identified 1,402 TCM users and 1,402 non-TCM users after frequency matching (Figure 1). Table 1 shows baseline characteristics of the migraine patients in the TCM and non-TCM groups. The mean ages were 51.20 (standard deviation [SD], ± 16.57) years and 51.32 (SD, ± 16.61) years for the TCM and non-TCM users, respectively. The percentages of females and males were 50.43% and 49.57%, respectively. Compared with non-TCM users, TCM users had significantly higher proportions of comorbidity with hyperlipidemia. The mean follow-up periods were 7.00 (median = 6.31) and 5.56 (median = 4.91) years for the TCM and non-TCM groups, respectively.

A total of 134 subjects were newly diagnosed with dementia during the follow-up period. Table 2 displays univariate and multivariate Cox proportional hazards models for TCM users vs. non-TCM users during the years 1997–2013. After adjusting for age, sex, diabetes mellitus (DM), hypertension, coronary artery disease (CAD), head injury, depression, hyperlipidemia, stroke, mental disorder, chronic kidney disease, and renal dialysis, TCM users were significantly less likely to develop dementia (adjusted hazard ratio [aHR], 0.65; 95% confidence interval [CI], 0.46–0.95) than non-TCM users. Compared to the ≥ 80 years group, there was lower risk of developing dementia in the 40–49 years (aHR, 0.01; 95% CI, 0–0.05), 50–59 years (aHR, 0.03; 95% CI, 0.01–0.08), 60–69 years (aHR, 0.22; 95% CI, 0.13–0.38), and the 70–79 years (aHR, 0.55; 95% CI, 0.35–0.88) groups. Patients with depression had a higher risk of developing dementia (aHR, 2.43; 95% CI, 1.52–3.89) in the Cox proportional hazards model.

In Table 3, stratified by gender, the incidence rates of dementia in females and males among TCM users were 6.48 and 7.35 per 1,000 person-years, respectively; lower than the corresponding rates in the non-TCM users (9.08 and 7.83 per 1,000 person-years for females and males, respectively). In addition, female TCM users had a 0.48-fold lower risk of developing dementia than non-TCM users (95% CI: 0.29–0.81). Among the 70–79 years group, TCM users had significantly lower risk than non-TCM users (aHR, 0.6; 95% CI, 0.37–0.99). TCM users with diabetes mellitus and hypertension were less likely to have dementia than those who were non-TCM users (aHR, 0.39; 95% CI, 0.21–0.71 vs. aHR, 0.54; 95% CI, 0.36–0.82, respectively). The Kaplan-Meier analysis with log-rank test showed a lower cumulative incidence of dementia in TCM users than in non-TCM users (P = 0.2458; Figure 2).

Table 4 shows that migraine patients who received only CHPs or combined CHPs with acupuncture/Tuina treatment had significantly lower risk of developing dementia than non-TCM users (aHR, 0.6; 0.39–0.92 vs. aHR, 0.62; 95% CI, 0.40–0.97, respectively). Table 5 presents the top 10 single CHPs and the top 10 formulae CHPs prescribed to migraine patients. In Table 6, the hazard ratios (HR) of the 10 single CHPs and the 10 formulae CHPs most commonly prescribed to migraine patients are shown. The majority of the single CHPs (except for Dan-Shen, Chuan-Xiong, and Jie-Geng) and
all but two of the formulae CHPs (Jia-Wei-Xiao-Yao-San and Ger-Gen-Tang) were associated with significant reductions in HR.

**DISCUSSION**

In this nationwide cohort study, we identified migraine patients and compared the risks of developing dementia between TCM users and non-TCM users. The main findings were as follows: (1) TCM use may prevent dementia in migraine patients because it was associated with a 0.65-fold lower risk. (2) Compared with controls, older migraine patients or those with depression had a higher risk of developing dementia, but TCM use could reduce the risk of dementia in migraine patients aged 70–79 years. (3) The most common formulae CHPs prescribed were Jia-Wei-Xiao-Yao-San (JWXYS) and Chuan-Xiong-Cha-Tiao-San (CXCTS), and the most common single CHPs prescribed were Yan-Hu-Suo (*Corydalis yanhusuo*) and Da-Huang (*Rheum palmatum*).

Migraine has traditionally been considered a disorder caused by brain dysfunction and trigeminovascular nociception that does not involve structural brain abnormalities [10]. However, recent studies have shown that migraine may be a risk factor for structural changes in the brain, including increased risk of deep white matter lesions and subclinical posterior circulation infarcts [10–14]. These white matter abnormalities and silent infarct lesions may increase vascular cognitive impairment, also known vascular dementia [15]. It has also been reported that migraine patients have a higher prevalence of psychiatric comorbidities compared with the general population [16]. These psychiatric comorbidities in migraine patients, including depression, anxiety, bipolar

---

**Figure 1: The participant selection process in the study and comparison cohorts.**
disorder, and post-traumatic stress disorder [16], are reportedly associated with an increased risk of late-life dementia [17, 18].

As global average life expectancy increases, the number of people with dementia is expected to reach 75 million by 2030, and 131 million by 2050 [9]. Dementia will therefore have a huge economic impact in the future. Dementia is a multifactorial disorder influenced by interaction between genetic and environmental factors over the lifespan. The optimal strategy for preventing dementia is multifactorial intervention with simultaneous management of various risks, and protective lifestyle changes and pharmacological treatments [9]. Several drugs (antihypertensive drugs, statins, hormone replacement therapy, and non-steroidal anti-inflammatory drugs), and dietary and nutritional advice (Mediterranean diet, polyunsaturated fatty acids and fish-related fats, vitamins B6, B12, and folate, and antioxidant vitamins) have been proposed and investigated for dementia prevention, but the evidence to date is variable [9]. Possible reasons and limitations in these studies include different study designs, inappropriate timing and duration of interventions, and single-agent intervention in clinical trials.

The use of CAM is increasing rapidly, now exceeding a prevalence of 53% among those aged 50 years and above in the US [19]. Traditional Chinese herbal medicine is the most common CAM for the prevention and treatment of dementia in Asian countries. Some conventional drugs used for dementia originate from plants, e.g., galantamine, rivastigmine, Huperzine A, extracts of Ginkgo biloba, etc. [20]. Generally, TCM doctors prescribe one or two main formulae combined with several single herbs in clinical practice, as was indicated in our study. Herbal products contain complex mixtures of active components (phytochemicals), including phenylpropanoids, isoprenoids, and alkaloids [21]. Herbal medicine is reportedly associated with significant improvement in the symptoms of dementia, but it is often difficult to determine which components of the herb or herbs have biological activity [21–23]. Thus, the role of herbal medicine in the clinical management of dementia is yet to be determined. As Chinese herbal medicines contain multiple compounds and phytochemicals that may have multifaceted neuroprotective effects, they may prove beneficial in different neuropsychiatric and neurodegenerative disorders [24].

Our results are consistent with those of a previous observational study in that the most common formulae CHPs used among migraine patients in Taiwan were JWXYS and CXCTS [25]. Generally, JWXYS is used to relieve hot flushes and other menopausal symptoms, sleep disorders, and emotional disturbances [26–28]. It is of note that JWXYS is also a common formula used in patients with dementia, hypertension, and hyperlipidemia as suggested by various observational studies [29–32]. However, to date there is no relevant literature regarding the vascular effect of JWXYS on dementia or hypertension, except for one recent study that showed that it can inhibit smooth muscle cell contractility by measuring the phosphorylation of myosin light chain protein and using the collage contraction assay [30]. JWXYS reportedly inhibits the production and expression of nitric oxide, inducible nitric oxide synthase (iNOS), prostaglandin E$_2$, cyclooxygenase-2, tumor necrosis factor-α, and interleukin-6 in lipopolysaccharide-stimulated RAW 264.7 macrophages [33], suggesting

Figure 2: Cumulative rate of dementia in non-TCM and TCM users during the follow-up period in the migraine cohort.
that it may have potent anti-inflammatory activity in the treatment and prevention of inflammatory processes or diseases. Additionally, JWXYS reportedly has antioxidant and neuroprotective effects, especially in mesencephalic dopaminergic cells, suggesting that it may be useful for the treatment of postmenopausal depression related to the degeneration of dopamine neurons [34]. In our study, nearly all the formulae were associated with significant reductions in the risk of developing dementia. Despite a lack of studies on their neuroprotective effects, several herbs among these formulae have been shown to have sedative, antioxidant, or anti-inflammatory effects, including *Glycyrrhiza uralensis* (Gan-Cao), *Angelicae sinensis* (Dang-Gui), and *Ligusticum chuanxiong* (Chuan-Xiong) [25]. Further studies may focus on the antioxidant or anti-inflammatory activities exerted by specific molecules present in prescribed herbal medicines.

In this study, most of the commonly used single CHPs were associated with a significant reduction in the risk of developing dementia in migraine patients, except Dan-Shen, Chuan-Xiong, and Jie-Geng. The most frequently prescribed single CHP, Yan-Hu-Suo (*Corydalis yanhusuo*), is used in TCM for pain relief and blood activation. L-tetrahydropalmatine (L-THP), identified as one of the major active components of Yan-Hu-Suo, has been used to treat headache and chemotherapy-induced pain, and also exerted a significant antinociceptive effect on chronic inflammatory and neuropathic pain.

Table 1: Characteristics of migraine patients according to use of TCM and non-used

| Variable | Migraine patients | TCM | P-value |
|----------|-------------------|-----|---------|
|          | No (n = 1402)     | Yes (n = 1402) |       |
|          | n | % | n | % |
| Sex      |   |   |   |   |
| Female   | 695 | 49.57 | 695 | 49.57 | 0.99* |
| Male     | 707 | 50.43 | 707 | 50.43 |     |
| Age group|   |   |   |   |
| 20–29    | 165 | 11.77 | 165 | 11.77 | 0.99* |
| 30–39    | 229 | 16.33 | 229 | 16.33 |     |
| 40–49    | 307 | 21.9 | 307 | 21.9 |     |
| 50–59    | 259 | 18.47 | 259 | 18.47 |     |
| 60–69    | 191 | 13.62 | 191 | 13.62 |     |
| 70–79    | 200 | 14.27 | 200 | 14.27 |     |
| More than 80 | 51 | 3.64 | 51 | 3.64 |     |
| Mean ± Standard Deviation (years) | 51.32 (16.61) | 51.20 (16.57) | < .0001* |
| Co-morbidity |   |   |   |   |
| Diabetes mellitus | 212 | 15.12 | 253 | 18.05 | 0.0374* |
| Hypertension | 565 | 40.3 | 532 | 37.95 | 0.2016* |
| Coronary artery disease | 219 | 15.62 | 246 | 17.55 | 0.1704* |
| Head injury | 59 | 4.21 | 83 | 5.92 | 0.0387* |
| Depression | 92 | 6.56 | 119 | 8.49 | 0.0532* |
| Hyperlipidemia | 295 | 21.04 | 385 | 27.46 | < 0.0001* |
| Stroke | 276 | 19.69 | 287 | 20.47 | 0.6041* |
| Mental disorders | 1 | 0.07 | 1 | 0.07 | 0.99* |
| Chronic kidney disease | 26 | 1.85 | 39 | 2.78 | 0.1028* |
| Renal dialysis | 1 | 0.07 | 1 | 0.07 | 0.99* |
| Duration between migraine date and index, days (mean, median) | 983 (695) | 953 (663) |     |
| Follow time (mean, median) | 5.56 (4.91) | 7.00 (6.31) |     |

*Chi-square test; *t*-test; *Fisher’s exact test.
in a mouse model, without associated motor deficits [35]. Dehydrocorybulbine, another active component of Yan-Hu-Suo, is also reportedly effective against inflammatory pain and injury-induced neuropathic pain [36]. Acetylcholinesterase (AChE) inhibitors are widely used for the symptomatic treatment of Alzheimer’s disease (AD) and other dementias. Previous research has shown that compounds isolated from Yan-Hu-Suo, including berberine, palmatine, jatrorrhizine, coptisine, and dehydrocorydaline, had dose-dependent inhibitory effects on AChE activity [37]. Increasing evidence demonstrates that beta-amyloid (A-beta) elicits oxidative stress, which contributes to the pathogenesis and progression of AD [38]. Thus, there is interest in developing antioxidant therapies for the prevention or treatment of cognitive decline during AD. Rhein, puerarin, and imperatorin, which are major medicinal ingredients isolated from Da-Huang (Rheum palmatum), Ge-Gen (Pueraria lobata), and Bai-Zhi (Angelica dahurica), respectively, reportedly exert antioxidant effects [39–41]. Another single CHP, Dan-Shen (Salvia miltiorrhiza), a well-known TCM herb used for the treatment of cerebrovascular diseases including stroke, has also been shown to have positive effects in neurodegenerative diseases. The main bioactive constituents of Dan-Shen are the lipophilic diterpenic quinones known as tanshinones, and the

Table 2: Cox model with hazard ratios and 95% confidence intervals of dementia associated with TCM and covariates among migraine patients

| Variable                      | No. of events (n = 134) | Crude* | P-value | Adjusted† | P-value |
|------------------------------|-------------------------|--------|---------|-----------|---------|
| TCM                          |                         |        |         |           |         |
| No                           | 66                      | 1.00   | reference | 1.00     | reference |
| Yes                          | 68                      | 0.84   | (0.6–1.19) | 0.3277  | 0.65    | (0.46–0.92) | 0.0152 |
| Sex                          |                         |        |         |           |         |
| Female                       | 67                      | 1.00   | reference | 1.00     | reference |
| Male                         | 67                      | 0.99   | (0.71–1.39) | 0.9656  | 0.78    | (0.55–1.11) | 0.1706 |
| Age group                    |                         |        |         |           |         |
| 20–29                        | 0                       | -      | -       | -         | -       |
| 30–39                        | 0                       | -      | -       | -         | -       |
| 40–49                        | 3                       | 0.01   | (0–0.04) | < 0.0001 | 0.01    | (0–0.05) | < 0.0001 |
| 50–59                        | 6                       | 0.03   | (0.01–0.07) | < 0.0001 | 0.03    | (0.01–0.08) | < 0.0001 |
| 60–69                        | 31                      | 0.21   | (0.13–0.36) | < 0.0001 | 0.22    | (0.13–0.38) | < 0.0001 |
| 70–79                        | 69                      | 0.52   | (0.33–0.82) | 0.0054  | 0.55    | (0.35–0.88) | 0.0134 |
| ≥ 80                         | 25                      | 1.00   | reference | 1.00     | reference |
| Comorbidity (ref = no comorbidities) |                 |        |         |           |         |
| Diabetes mellitus            | 48                      | 3.16   | (2.22–4.5) | < 0.0001 | 1.41    | (0.96–2.08) | 0.079 |
| Hypertension                 | 99                      | 5.00   | (3.4–7.36) | < 0.0001 | 1.07    | (0.7–1.63) | 0.7617 |
| Coronary artery disease      | 51                      | 3.43   | (2.42–4.86) | < 0.0001 | 1.07    | (0.73–1.57) | 0.71 |
| Head injury                  | 7                       | 1.15   | (0.54–2.46) | 0.7228  | 0.82    | (0.38–1.77) | 0.6118 |
| Depression                   | 23                      | 2.85   | (1.82–4.47) | < 0.0001 | 2.43    | (1.52–3.89) | 0.0002 |
| Hyperlipidemia               | 51                      | 1.97   | (1.39–2.8)  | 0.0001  | 0.88    | (0.6–1.3) | 0.5116 |
| Stroke                       | 66                      | 4.29   | (3.06–6.02) | < 0.0001 | 1.24    | (0.86–1.78) | 0.2539 |
| Mental disorders             | 0                       | -      | -       | -         | -       |
| Chronic kidney disease       | 6                       | 2.32   | (1.02–5.27) | 0.0437  | 0.71    | (0.3–1.64) | 0.4191 |
| Renal dialysis               | 0                       | -      | -       | -         | -       |

Abbreviations: CI, confidence interval; HR, hazard ratio; TCM, traditional Chinese medicine. Crude HR represents the relative hazard ratio. Adjusted HR represents the adjusted hazard ratio; mutually adjusted for TCM, age, sex, diabetes mellitus, hypertension, coronary artery disease, head injury, depression, hyperlipidemia, stroke, mental disorders, chronic kidney disease, and renal dialysis in the Cox proportional hazards regression.
| Variables                      | TCM                          | Crude HR                  | Adjusted HR                |
|-------------------------------|------------------------------|---------------------------|----------------------------|
|                               | (n = 1402)                  | (95% CI)                  | (95% CI)                   |
|                               | Event Person-years IR†       | Event Person-years IR†    |                            |
| Total                         | 66                           | 68                        | 9820                       | 6.92                       | 0.84 (0.60–1.19) | 0.65 (0.46–0.92)* |
| Sex                           |                              |                           |                            |                            |                            |                |
| Female                        | 36                           | 31                        | 4785                       | 6.48                       | 0.72 (0.45–1.17) | 0.48 (0.29–0.81)** |
| Male                          | 30                           | 37                        | 5035                       | 7.35                       | 1.0 (0.62–1.63) | 0.8 (0.49–1.31)    |
| Age group                     |                              |                           |                            |                            |                            |                |
| 20–29                         | 0                            | 0                         | 1205                       | 0.00                       | -                          | -                |
| 30–39                         | 0                            | 0                         | 1671                       | 0.00                       | -                          | -                |
| 40–49                         | 2                            | 1                         | 2189                       | 0.46                       | 0.32 (0.03–3.58) | 0.19 (0.01–3.95) |
| 50–59                         | 3                            | 3                         | 1808                       | 1.66                       | 0.9 (0.18–4.45) | 0.79 (0.15–4.17) |
| 60–69                         | 15                           | 16                        | 1379                       | 11.60                      | 0.82 (0.4–1.66) | 0.86 (0.42–1.77) |
| 70–79                         | 35                           | 34                        | 1311                       | 25.93                      | 0.64 (0.4–1.04) | 0.6 (0.37–0.99)* |
| ≥ 80                          | 11                           | 14                        | 257                        | 54.40                      | 0.76 (0.34–1.68) | 0.49 (0.21–1.15) |
| Comorbidity                   |                              |                           |                            |                            |                            |                |
| Diabetes mellitus             |                              |                           |                            |                            |                            |                |
| No                            | 40                           | 46                        | 8143                       | 5.65                       | 0.99 (0.65–1.51) | 0.8 (0.51–1.24)    |
| Yes                           | 26                           | 22                        | 1677                       | 13.12                      | 0.51 (0.29–0.9) | 0.39 (0.21–0.71)** |
| Hypertension                  |                              |                           |                            |                            |                            |                |
| No                            | 12                           | 23                        | 6263                       | 3.67                       | 1.57 (0.78–3.17) | 1.02 (0.49–2.14) |
| Yes                           | 54                           | 45                        | 3557                       | 12.65                      | 0.67 (0.45–0.99) | 0.54 (0.36–0.82)** |
| Coronary artery disease       |                              |                           |                            |                            |                            |                |
| No                            | 42                           | 41                        | 8228                       | 4.98                       | 0.82 (0.53–1.27) | 0.61 (0.39–0.95)* |
| Yes                           | 24                           | 27                        | 1592                       | 16.96                      | 0.77 (0.44–1.33) | 0.7 (0.39–1.26)    |
| Head injury                   |                              |                           |                            |                            |                            |                |
| No                            | 62                           | 65                        | 9317                       | 6.98                       | 0.87 (0.61–1.24) | 0.65 (0.46–0.94)* |
| Yes                           | 4                            | 3                         | 503                        | 5.97                       | 0.47 (0.11–2.11) | 0.3 (0.05–1.85)    |
| Depression                    |                              |                           |                            |                            |                            |                |
| No                            | 60                           | 51                        | 9115                       | 5.60                       | 0.7 (0.48–1.02) | 0.59 (0.4–0.86)** |
| Yes                           | 6                            | 17                        | 705                        | 24.12                      | 1.92 (0.76–4.86) | 1.17 (0.41–3.35) |
| Hyperlipidemia                |                              |                           |                            |                            |                            |                |
| No                            | 46                           | 37                        | 7239                       | 5.11                       | 0.72 (0.46–1.11) | 0.55 (0.35–0.86)** |
| Yes                           | 20                           | 31                        | 2581                       | 12.01                      | 0.95 (0.54–1.68) | 0.78 (0.43–1.41) |
| Stroke                        |                              |                           |                            |                            |                            |                |
| No                            | 34                           | 34                        | 7892                       | 4.31                       | 0.84 (0.52–1.36) | 0.61 (0.37–1.01) |
| Yes                           | 32                           | 34                        | 1928                       | 17.64                      | 0.75 (0.46–1.22) | 0.66 (0.4–1.1)    |
| Mental disorders              |                              |                           |                            |                            |                            |                |
| No                            | 66                           | 68                        | 9816                       | 6.93                       | 0.84 (0.6–1.19) | 0.64 (0.45–0.91)* |
| Yes                           | 0                            | 4                         | 0                          | 0.00                       | -                          | -                |
| Chronic kidney disease        |                              |                           |                            |                            |                            |                |
| No                            | 65                           | 63                        | 9585                       | 6.57                       | 0.8 (0.57–1.13) | 0.62 (0.44–0.89)** |
| Yes                           | 1                            | 5                         | 235                        | 21.28                      | 2.47 (0.29–21.23) | 2.53 (0.06–115.1) |
hydrophilic depsides known as salvianolic acids [42].
Both tanshinones and depsides can protect against A-beta-
induced toxicity, and have anti-inflammatory activity [42].
Tanshinone IIA has been shown to reduce the risk
of AD by inhibiting iNOS, matrix metalloproteinase-2,
and nuclear transcription factor kappa transcription and
translation in the temporal lobes of rat models of AD [43].

The occurrence of AD and other dementias is higher
in women than in men, particularly in the most elderly,
and the burden of dementias is greater for women than for men
[44]. In our study, gender was not a significant risk factor
for developing dementia among migraine patients. The
female TCM users had a 52% lower risk compared with
non-TCM users. TCM may be more effective in females
than in males. The cause is unknown, and possible reasons
include genetic factors, hormonal factors, and/or a higher
prevalence of unhealthy lifestyles in men such as smoking
and alcohol use. The risk of developing dementia increased
with age in migraine patients, but only patients aged 70
to 79 years who used TCM had a significant reduction in
HR. A possible reason is that early onset dementia may be
more attributable to traumatic brain injury, alcohol use,
human immunodeficiency virus, and frontotemporal lobar
degeneration than late onset dementia [45]. TCM may be
more effective in the prevention of late onset dementia
that is mainly caused by AD, but not in those older than
80 years.

In our clinical practice, migraine patients received
TCM treatment including Chinese herbal medicine,
acupuncture, and Tuina. Acupuncture has been
reported to improve cognitive function in those with
dementia by regulating glucose metabolism, enhancing
neurotransmission and reducing oxidative stress, Aβ
protein deposition, and neuronal apoptosis in animal
studies [46, 47]. In our study, migraine patients who
accepted CHP treatment alone, or that combined with
acupuncture/Tuina, had significant reduction in HR
compare to non-TCM users. TCM users who accepted
only acupuncture/Tuina treatment had no significant
reduction in HR compared to non-TCM users. Therefore,
acupuncture/Tuina did not have a preventive effect on
the development of dementia in our study. However, the
sample of patients who received only acupuncture/Tuina
was small and sampling bias may have occurred. Larger
clinical trials should be designed to determine the effects
of acupuncture/Tuina on dementia development.

The strengths of this study include the immediate
availability and comprehensiveness of the nationwide
database. In addition, this 15-year follow-up study allowed
us to examine the use of TCM confidently with regard to
associations between migraine and the risk of dementia
over a long latency period. Despite these strengths, several
limitations should be noted when interpreting the results
of the present study. First, the identification of TCM
exposure and outcomes were based on ICD-9-CM codes,
and misclassification is a possibility. To minimize this
potential error, we selected subjects with either migraine or
dementia only after they were recorded as having at least
two ambulatory or inpatient claims reporting consistent
diagnoses. Second, information on lifestyle factors,

Table 4: Hazard ratios and 95% confidence intervals of dementia risk associated with acupuncture/
Tuina treatment among the migraine patients

| No. of | Person- | IR  | Crude HR  | Adjusted HR*  | Crude HR  | Adjusted HR*  |
|-------|---------|-----|-----------|---------------|-----------|---------------|
| events| years   |     |           | (95% CI)      | (95% CI)  | (95% CI)      |
| Non-TCM users | 66    | 7797 | 8.46 | 1 (reference) | 1 (reference) | -             | -             |
| TCM users |       |     |     |           |           |               |               |
| Only CHPs | 34    | 4237 | 8.03 | 0.96 (0.63–1.45) | 0.60 (0.39–0.92)* | 1.47 (0.90–2.40) | 1.01 (0.61–1.68) |
| Only acupuncture/ Tuina | 4     | 130  | 30.76 | 3.61 (1.31–9.90)* | 2.19 (0.79–6.12) | 5.62 (1.97–15.98)** | 4.46 (1.52–13.08)** |
| Combined CHPs and acupuncture/Tuina | 30    | 5453 | 5.5  | 0.68 (0.44–1.05) | 0.62 (0.40–0.97)* | 1 (reference) | 1 (reference) |

Abbreviations: CHPs, Chinese herbal products; CI, confidence interval; HR, hazard ratio; IR, incidence rates, per 1,000 person-years; TCM, traditional Chinese medicine. *Adjusted HR represents adjusted hazard ratio; mutually adjusted for age, sex, diabetes mellitus, hypertension, coronary artery disease, head injury, depression, hyperlipidemia, stroke, mental disorders, chronic kidney disease, and renal dialysis in the Cox proportional hazards regression.

*P < 0.05; **P < 0.01.
Oncotarget

www.impactjournals.com/oncotarget

education levels, and nutritional factors were not available from the National Health Insurance Research Database (NHIRD). Sedentary lifestyle, smoking, heavy alcohol consumption, lower education level, and deficiencies in vitamins B6, B12, D, and folate are associated with an increased risk of dementia [9]. The failure to adjust for putative risk factors may have resulted in biased estimates of risks of dementia in our sample. Third, we were not sure whether the patients exactly took medication as their physicians prescribed or not. Other preparations of Chinese herbal remedies, health foods containing natural herbs, folk medicine, and direct purchases from TCM herbal pharmacies are not reimbursed by NHI, and therefore, were not analyzed in this study. However, the high healthcare insurance coverage and low prices of government-approved CHPs have led to a reduction in herbal folk medicine use. Furthermore, prescriptions for medications issued before 1996 were not reflected in the data analysis in the present study. This omission could possibly result in underestimating cumulative frequencies, and may have weakened the effect of the specified CHPs.

In conclusion, this 15-year follow-up cohort study found that the use of TCM during the treatment of migraine was associated with a 35% lower risk of developing dementia compared with the risk among non-TCM users. This finding was statistically significant, and could serve as a strong reference for healthcare providers to help establish more effective therapeutic interventions to improve the prognosis of patients with migraine.

### MATERIALS AND METHODS

**Data sources**

Taiwan’s compulsory universal NHI program was developed in 1995 by the NHI Administration (NHIA), and provided coverage to more than 23.03 million residents in Taiwan at the time. In 2008, > 99% of the Taiwanese population was enrolled in the NHI program. Reimbursed TCM services included CHPs, and acupuncture or moxibustion in ambulatory clinics. The database (http://nhird.nhri.org.tw/date_01_en.html) contains all longitudinal reimbursement information on sex, birth date, medications, and diagnosis codes based on the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). We used the Longitudinal Health Insurance Database 2000 (LHID 2000), which contains medical information on 1 million beneficiaries randomly sampled from the registry of all beneficiaries in 2000. As a group, the sampled patients

---

**Table 5: Ten most common single and formulae CHPs prescribed for migraine in Taiwan**

| CHPs                        | Frequency | Number of person-days | Average daily dose (g) | Average duration of prescription (days) |
|-----------------------------|-----------|-----------------------|------------------------|----------------------------------------|
| **Single CHP**              |           |                       |                        |                                        |
| Yan-Hu-Suo                  | 1837      | 13416                 | 2                      | 7.3                                    |
| Da-Huang                    | 1610      | 12593                 | 2                      | 7.8                                    |
| Ge-Gen                      | 1436      | 11376                 | 6.6                    | 7.9                                    |
| Dan-Shen                    | 1408      | 11614                 | 3.6                    | 8.2                                    |
| Bai-Zhi                     | 1367      | 9726                  | 11.2                   | 7.1                                    |
| Zhe-Bei-Mu                  | 1278      | 9747                  | 3.4                    | 7.6                                    |
| Chuan-Xiong                 | 1254      | 10143                 | 5.6                    | 8.1                                    |
| Huang-Qin                   | 1114      | 8291                  | 2.3                    | 7.4                                    |
| Jie-Geng                    | 1076      | 7043                  | 3.4                    | 6.5                                    |
| Gan-Cao                     | 1015      | 7709                  | 1.3                    | 7.6                                    |
| **Formulae CHP**            |           |                       |                        |                                        |
| Jia-Wei-Xiao-Yao-San        | 1963      | 16688                 | 17.6                   | 8.5                                    |
| Chuan-Xiong-Cha-Tiao-San    | 1857      | 13049                 | 10.4                   | 7                                      |
| Shu-Jing-Huo-Xie-Tang       | 1586      | 10547                 | 7.5                    | 6.7                                    |
| Ji-Sheng-Shen-Qi-Wan        | 1290      | 12040                 | 12.4                   | 9.3                                    |
| Ger-Gen                     | 1242      | 8216                  | 16.4                   | 6.6                                    |
| Ban-Xia-Xie-Xin-Tang        | 1235      | 9505                  | 12.2                   | 7.7                                    |
| Xue-Fu-Zhu-Yu-Tang          | 1222      | 9832                  | 7.6                    | 8                                      |
| Shao-Yao-Gan-Cao-Tang       | 1175      | 8205                  | 5.9                    | 7                                      |
| Siang-Sha-Liu-Jun-Zi-Tang   | 991       | 8257                  | 7.2                    | 8.3                                    |
| Zhi-Gan-Cao-Tang            | 942       | 6786                  | 5.7                    | 7.2                                    |

CHP, Chinese herbal product.
exhibit no significant differences in age, sex, birth year, or average insured payroll-related amount from the general population. The requirement for informed consent was waived because the National Health Insurance Research Database contains anonymized secondary data for research. This study was approved by the Institutional Review Board of China Medical University (CMUH104-REC2-115).

**Study population**

Patients who were newly diagnosed with migraine between 1997 and 2010 were identified as the migraine cohort. The population with migraine \( n = 36,865 \) were required to have had at least two ambulatory or inpatient claims with a diagnosis of ICD-9-CM code 346, from 1997 to 2010. We excluded patients younger than 20 years, those who had withdrawn from the NHI program within a year of follow-up, and those diagnosed with dementia before their initial diagnosis of migraine. We also excluded those who utilized TCM treatment before the initial diagnosis of migraine, but did not utilize TCM treatment during the follow-up period. For each category of migraine patients, those who had at least one TCM outpatient clinical record were defined as TCM users during the follow-up period \( n = 28,456 \), whereas those who had no TCM outpatient records were defined as non-TCM-users \( n = 1,656 \); (Figure 1). In the TCM patient group, the index date was

---

**Table 6: Hazard ratios and 95% confidence intervals of dementia risk associated with CHPs used by migraine patients in Taiwan**

| CHPs                  | Dementia | Hazard ratio (95% CI) |
|-----------------------|----------|----------------------|
|                       |          | n                    | No. of events | Crude* | Adjusted† |
| Non-TCM user          |          | 1402                 | 66            | 1.00   | 1.00       |
| Single CHP            |          |                      |               |        |            |
| Yan-Hu-Suo            |          | 441                  | 15            | 0.56   | 0.50       |
|                       |          |                      |               | (0.32–0.98)* | (0.28–0.89)* |
| Da-Huang              |          | 207                  | 5             | 0.40   | 0.36       |
|                       |          |                      |               | (0.16–0.98)* | (0.14–0.93)* |
| Ge-Gen                |          | 328                  | 7             | 0.35   | 0.29       |
|                       |          |                      |               | (0.16–0.76)** | (0.13–0.65)** |
| Dan-Shen              |          | 284                  | 9             | 0.54   | 0.57       |
|                       |          |                      |               | (0.27–1.09) | (0.28–1.18) |
| Bai-Zhi               |          | 285                  | 7             | 0.40   | 0.44       |
|                       |          |                      |               | (0.18–0.87)* | (0.20–0.97)* |
| Zhe-Bei-Mu            |          | 263                  | 6             | 0.37   | 0.36       |
|                       |          |                      |               | (0.16–0.86)* | (0.15–0.86)* |
| Chuan-Xiong           |          | 273                  | 13            | 0.76   | 0.57       |
|                       |          |                      |               | (0.42–1.38) | (0.31–1.07) |
| Huang-Qin             |          | 267                  | 2             | 0.12   | 0.16       |
|                       |          |                      |               | (0.03–0.50)** | (0.04–0.65)* |
| Jie-Geng              |          | 248                  | 7             | 0.46   | 0.46       |
|                       |          |                      |               | (0.21–1.01) | (0.21–1.02) |
| Gan-Cao               |          | 255                  | 6             | 0.39   | 0.33       |
|                       |          |                      |               | (0.17–0.89)* | (0.14–0.78)* |

**Formulae CHP**

|                       |          |                      |               |        |            |
| Jia-Wei-Xiao-Yao-San  |          | 362                  | 13            | 0.59   | 0.69       |
|                       |          |                      |               | (0.32–1.07) | (0.36–1.30) |
| Chuan-Xiong-Cha-Tiao-San |    | 338                  | 12            | 0.57   | 0.49       |
|                       |          |                      |               | (0.31–1.06) | (0.26–0.93)* |
| Shu-Jing-Huo-Xie-Tang |          | 401                  | 15            | 0.60   | 0.49       |
|                       |          |                      |               | (0.34–1.06) | (0.28–0.88)* |
| Ji-Sheng-Shen-Qi-Wan  |          | 179                  | 5             | 0.46   | 0.35       |
|                       |          |                      |               | (0.18–1.14) | (0.14–0.87)* |
| Ger-Gen-Tang          |          | 357                  | 9             | 0.42   | 0.50       |
|                       |          |                      |               | (0.21–0.84)* | (0.25–1.02) |
| Ban-Xia-Xie-Xin-Tang  |          | 238                  | 4             | 0.27   | 0.25       |
|                       |          |                      |               | (0.10–0.75)* | (0.09–0.71)** |
| Xue-Fu-Zhu-Yu-Tang    |          | 278                  | 8             | 0.45   | 0.39       |
|                       |          |                      |               | (0.22–0.95)* | (0.18–0.83)* |
| Shao-Yao-Gan-Cao-Tang |          | 363                  | 11            | 0.49   | 0.42       |
|                       |          |                      |               | (0.26–0.92)* | (0.22–0.82)* |
| Siang-Sha-Liu-Jun-Zi-Tang |   | 197                  | 6             | 0.49   | 0.41       |
|                       |          |                      |               | (0.21–1.13) | (0.17–0.98)* |
| Zhi-Gan-Cao-Tang      |          | 193                  | 7             | 0.62   | 0.42       |
|                       |          |                      |               | (0.28–1.36) | (0.19–0.94)* |

Abbreviations: CHP, Chinese herbal product; HR, hazard ratio; TCM, traditional Chinese medicine. Crude HR* represents the relative hazard ratio. Adjusted HR† represents the adjusted hazard ratio; mutually adjusted for Chinese herb usage, age, sex, diabetes mellitus, hypertension, coronary artery disease, head injury, depression, hyperlipidemia, stroke, mental disorders, chronic kidney disease, and renal dialysis in the Cox proportional hazards regression. *P < 0.05, **P < 0.01.
the first TCM treatment utilized after the initial diagnosis of migraine. In the non-TCM group, no index date for the first TCM treatment could be assigned. Thus, we randomly assigned a “pseudo diagnostic date” to each patient within the initial diagnosis date of migraine and the endpoint, as the index date for that group. The same eligibility criteria were applied to each group, yet the distributions of age and sex were unbalanced between groups. To balance comparability between the TCM and non-TCM groups, we randomly selected equal numbers from each group and compared the subgroups compiled based on combinations of age (5-year increments), sex, index year, and year of migraine diagnosis.

Outcome

The primary outcome was the occurrence of dementia, defined as the first ambulatory event or hospitalization with an ICD-9-CM code of 290.0–290.4, 294.1, 331.0, or 331.1–331.2, diagnosed by a neurologist, neurosurgeon, or psychiatrist during the follow-up period. Both cohorts were followed until December 31, 2013.

Covariate assessment

Sociodemographic factors included age and sex. Age was initially divided into 7 groups: 20–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and ≥ 80 years. Baseline comorbidities were considered to be present if ICD-9-CM codes appeared two or more times in the outpatient or inpatient claims before the initial diagnosis of migraine, and included diabetes mellitus (ICD-9-CM code 250), hypertension (ICD-9-CM code 401), coronary artery disease (CAD; ICD-9-CM codes 410–414), head injury (ICD-9-CM codes 850–854 and 959.01), hyperlipidemia (ICD-9-CM code 272), stroke (ICD-9-CM codes 430–438), mental disorder (ICD-9-CM codes V11, V79.9, and 310.9), chronic kidney disease (ICD-9-CM codes 585–586 and 403–404), and renal dialysis (ICD-9-CM codes V45.1 and V56).

Statistical analysis

Differences in demographic characteristics and comorbidities between the TCM and non-TCM groups were examined using the chi-squared test and two-sample t-test. Univariate and multivariate Cox proportional hazards models were used to evaluate the hazard ratios for dementia in the TCM group. The difference in the development of stroke between the two groups was estimated using the Kaplan-Meier method and the log-rank test. Statistical analysis was performed and figures were created using SAS 9.4 (SAS Institute, Cary, NC, USA) and R software. Statistical significance was defined as $P < 0.05$ in two-tailed tests.

Abbreviations

Ach: Acetylcholinesterase; AD: Alzheimer’s disease; CAD: coronary artery disease; CAM: complementary and alternative medicine; CHP: Chinese herbal product; CI: confidence interval; CXCTS: Chuan-Xiong-Cha-Tiao-San; DM: diabetes mellitus; HR: hazard ratio; ICD-9-CM: International Classification of Diseases 9th Revision Clinical Modification; iNOS: nitric oxide synthase; JWXYS: Jia-Wei-Xiao-Yao-San; LHID: Longitudinal Health Insurance Database; L-THP: L-tetrahydropalmatine; NHI: National Health Insurance; NHIRD: National Health Insurance Research Database; NTD: New Taiwan Dollars; OR: odds ratio; TCM: traditional Chinese medicine.

Authors’ contributions

YCH and WLH conceived and designed the study. WLH and JHC acquired and interpreted the data. CTL, BYW, YCH, and WLH drafted the manuscript. JHC analyzed the data. LYW, YYL, TKL, PHL, WFC and SFH critically revised the manuscript. All authors reviewed the manuscript.

ACKNOWLEDGMENTS AND FUNDING

We thank Prof. Chung Y. Hsu for his enthusiastic help in this work. This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan, Chang Gung Memorial Hospital (CMRPG8D0621). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CONFLICTS OF INTEREST

None declared.

REFERENCES

1. Friedman BW. Managing Migraine. Ann Emerg Med. 2017; 69:202–207.
2. Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27:193–210.
3. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin. 2009; 27:321–334.
4. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015; 55:21–34.

5. Scott KR, Barrett AM. Dementia syndromes: evaluation and treatment. Expert Rev Neurother. 2007; 7:407–422.

6. Chuang CS, Lin CL, Lin MC, Sung FC, Kao CH. Migraine and risk of dementia: a nationwide retrospective cohort study. Neuroepidemiology. 2013; 41:139–145.

7. NHIA. National Health Insurance Annual Report 2015–2016. National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, R.O.C., Taipei.

8. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014; 13:788–794.

9. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016; 15:455–532.

10. Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology. 2013; 81:1260–1268.

11. Lee MJ, Lee C, Chung CS. The Migraine-Stroke Connection. J Stroke. 2016; 18:146–156.

12. Kruit MC, van Buchem MA, Launer LJ, Terwindt GM, Ferrari MD. Migraine is associated with an increased risk of deep white matter lesions, subcortical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010; 30:129–136.

13. Kruit MC, van Buchem MA, Hofman PA, Bakkers JT, Terwindt GM, Ferrari MD, Launer LJ. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004; 291:427–434.

14. Hougaard A, Amin FM, Ashina M. Migraine and structural abnormalities in the brain. Curr Opin Neurol. 2014; 27:309–314.

15. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012; 7:61–73.

16. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016; 87:741–749.

17. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry. 2004; 75:1662–1666.

18. Zilkens RR, Bruce DG, Duke J, Spilsbury K, Semmens JB. Severe psychiatric disorders in mid-life and risk of dementia in late-life (age 65–84 years): a population based case-control study. Curr Alzheimer Res. 2014; 11:681–693.

19. Siddiqui MJ, Min CS, Verma RK, Jamshed SQ. Role of complementary and alternative medicine in geriatric care: A mini review. Pharmacogn Rev. 2014; 8:81–87.

20. May BH, Feng M, Zhou IW, Chang SY, Lu SC, Zhang AL, Guo XF, Lu CJ, Xue CC. Memory Impairment, Dementia, and Alzheimer’s Disease in Classical and Contemporary Traditional Chinese Medicine. J Altern Complement Med. 2016; 22:695–705.

21. Iriti M, Vitalini S, Fico G, Faoro F. Neuroprotective herbs and foods from different traditional medicines and diets. Molecules. 2010; 15:3517–3555.

22. May BH, Lit M, Xue CC, Yang AW, Zhang AL, Owens MD, Head R, Cobiac L, Li CG, Hugel H, Story DF. Herbal medicine for dementia: a systematic review. Phytother Res. 2009; 23:447–459.

23. Zeng L, Zou Y, Kong L, Wang N, Wang Q, Wang L, Cao Y, Wang K, Chen Y, Mi S, Zhao W, Wu H, Cheng S, et al. Can Chinese Herbal Medicine Adjunctive Therapy Improve Outcomes of Senile Vascular Dementia? Systematic Review with Meta-analysis of Clinical Trials. Phytother Res. 2015; 29:1843–1857.

24. Kumar GP, Khanum F. Neuroprotective potential of phytochemicals. Pharmacogn Rev. 2012; 6:81–90.

25. Chang YY, Tsai YT, Lai JN, Yeh CH, Lin SK. The traditional Chinese medicine prescription patterns for migraine patients in Taiwan: a population-based study. J Ethnopharmacol. 2014; 151:1209–1217.

26. Yeung WF, Chung KF, Ng KY, Yu YM, Ziea ET, Ng BF. A systematic review on the efficacy, safety and types of Chinese herbal medicine for depression. J Psychiatr Res. 2014; 57:165–175.

27. Chen YL, Lee CY, Huang KH, Kuan YH, Chen M. Prescription patterns of Chinese herbal products for patients with sleep disorder and major depressive disorder in Taiwan. J Ethnopharmacol. 2015; 171:307–316.

28. Chen HY, Lin YH, Wu JC, Chen YC, Yang SH, Chen JL, Chen TJ. Prescription patterns of Chinese herbal products for menopausal syndrome: analysis of a nationwide prescription database. J Ethnopharmacol. 2011; 137:1261–1266.

29. Chu SM, Shih WT, Yang YH, Chen PC, Chu YH. Use of traditional Chinese medicine in patients with hyperlipidemia: A population-based study in Taiwan. J Ethnopharmacol. 2015; 168:129–135.

30. Lin YJ, Ho TJ, Yeh YC, Cheng CF, Shiao YT, Wang CB, Chien WK, Chen JH, Liu X, Tsang H, Lin TH, Liao CC, Huang SM, et al. Chinese Herbal Medicine Treatment Improves the Overall Survival Rate of Individuals with Hypertension among Type 2 Diabetes Patients and Modulates In Vitro Smooth Muscle Cell Contractility. PLoS One. 2015; 10:e0145109.

31. Yang PR, Shih WT, Chu YH, Chen PC, Wu CY. Frequency and co-prescription pattern of Chinese herbal products for hypertension in Taiwan: a Cohort study. BMC Complement Altern Med. 2015; 15:163.
32. Lin SK, Tsai YT, Lai JN, Wu CT. Demographic and medication characteristics of traditional Chinese medicine users among dementia patients in Taiwan: a nationwide database study. J Ethnopharmacol. 2015; 161:108–115.

33. Jin SE, Kim OS, Yoo SR, Seo CS, Kim Y, Shin HK, Jeong SJ. Anti-inflammatory effect and action mechanisms of traditional herbal formula Gamisoyo-san in RAW 264.7 macrophages. BMC Complement Altern Med. 2016; 16:219.

34. Lee SH, Lee JM, Cho JH, Lee CH, Jang JB, Kim KS. Antioxidant and Neuroprotective Effects of Gamisoyo-san. J Orient Obstet Gynecol. 2010; 23:1–13.

35. Zhou HH, Wu DL, Gao LY, Fang Y, Ge WH. L-Tetrahydropalmatine alleviates mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain in mice. Neuroreport. 2016; 27:476–480.

36. Zhang Y, Wang C, Wang L, Parks GS, Zhang X, Guo Z, Ke Y, Li KW, Kim MK, Vo B, Borrelli E, Ge G, Yang L, et al. A novel analgesic isolated from a traditional Chinese medicine. Curr Biol. 2014; 24:117–123.

37. Xiao HT, Peng J, Liang Y, Yang J, Bai X, Hao XY, Yang FM, Sun QY. Acetylcholinesterase inhibitors from Corydalis yanhusuo. Nat Prod Res. 2011; 25:1418–1422.

38. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res. 2002; 36:1307–1313.

39. Cao Y, Zhang LW, Wang J, Du SQ, Xiao LY, Tu JF, Liu CZ. Mechanisms of Acupuncture Effect on Alzheimer’s Disease in Animal-Based Researches. Curr Top Med Chem. 2016; 16:574–578.

40. Ye Y, Zhu W, Wang XR, Yang JW, Xiao LY, Liu Y, Zhang X, Liu CZ. Mechanisms of acupuncture on vascular dementia-A review of animal studies. Neurochem Int. 2017; 107:204-210.